Prexton Therapeutics Archives

Home Prexton Therapeutics

Latest Posts

lundbeck prexton therapeutics acquisition parkinsons

News and Trends 16 Mar 2018

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful. Danish pharma Lundbeck has decided to boost its pipeline with the acquisition of Prexton Therapeutics. The deal grants Lundbeck with global rights to foliglurax, a drug to reduce the “off” time periods when Parkinson’s motor […]

March 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prexton’s foliglurax. The company is looking for patients that have been treated […]

July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

geneva biotech serono university of geneva

Best in Biotech 30 May 2017

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […]

May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro

News and Trends 7 Feb 2017

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson’s. An international team of top European biotech investors has participated in Prexton Therapeutics’ latest financing round. The €29M Series B round was co-led by the Dutch Forbion and the Irish Seroba Life Sciences, […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

For our first interview at the SACHS Conference in Basel yesterday, I met with François Conquet, founder and CEO of Prexton Therapeutics. His company’s treatment for Parkinson’s Disease just passed Phase I with flying colors. Prexton Therapeutics, based in Switzerland, has been focused on discovering new small molecules to treat Parkinson’s, and one of them, an mGluR4 positive […]

September 28, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us